

Andr  P legrin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2037961/publications.pdf>

Version: 2024-02-01

17
papers

802
citations

758635

12
h-index

794141

19
g-index

21
all docs

21
docs citations

21
times ranked

970
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 181-191.	3.7	146
2	Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent. <i>Annals of Surgical Oncology</i> , 2018, 25, 3350-3357.	0.7	110
3	Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. <i>Cancer</i> , 1991, 67, 2529-2537.	2.0	84
4	SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery. <i>Surgical Oncology</i> , 2017, 26, 153-162.	0.8	76
5	In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. <i>Clinical Cancer Research</i> , 2007, 13, 3356-3362.	3.2	75
6	In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. <i>Neoplasia</i> , 2012, 14, 121-130.	2.3	66
7	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial. <i>Oncotarget</i> , 2015, 6, 12796-12808.	0.8	56
8	HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. <i>Oncotarget</i> , 2014, 5, 7138-7148.	0.8	43
9	Different behaviour of mouse-human chimeric antibody F(ab') ₂ fragments of IgG1, IgG2 and IgG4 sub-class in vivo. <i>International Journal of Cancer</i> , 1992, 50, 416-422.	2.3	25
10	Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of antibodies in nude rats and as rejection antigen in syngeneic rats. <i>International Journal of Cancer</i> , 1992, 52, 110-119.	2.3	17
11	Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: A model for radioimmunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 67, 294-302.		16
12	Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. <i>Toxicology Reports</i> , 2019, 6, 409-415.	1.6	15
13	Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using ¹¹¹ In-Labeled SGM-101. <i>Clinical Cancer Research</i> , 2020, 26, 5934-5942.	3.2	14
14	High level prokaryotic expression of anti-Allergic inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging. <i>Journal of Immunological Methods</i> , 2013, 387, 11-20.	0.6	9
15	Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. <i>Cancers</i> , 2021, 13, 4620.	1.7	9
16	MABImprove. <i>MAbs</i> , 2014, 6, 803-804.	2.6	5
17	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. <i>MAbs</i> , 2021, 13, 1914883.	2.6	4